[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

NeuroSense Therapeutics Ltd. held a Special Meeting of Shareholders on March 10, 2026. At this meeting, shareholders approved a resolution to amend the company’s articles of association in order to increase the company’s registered share capital, expanding the amount of equity the company is authorized to issue in the future.

The report also states that this information is incorporated by reference into NeuroSense’s existing registration statements on Form S-8 and Form F-3, meaning those shelf and employee benefit registrations now reflect the updated corporate authorization.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of March 2026

Commission File Number: 001-41084

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-9531142
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

Special Meeting of Shareholders

On March 10, 2026, NeuroSense Therapeutics Ltd. (the “Company”) held a Special Meeting of Shareholders (the “Meeting”). At the Meeting, the shareholders approved the resolution to amend the Company’s articles of association to increase the registered share capital of the Company.

This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480 and 333-289658) and Form F-3 (File No. 333-269306, 333-260338, 333-283656, 333-284051, 333-291122 and 333-293060) to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NeuroSense Therapeutics Ltd.
Date: March 11, 2026	By:	/s/ Alon Ben-Noon
		Alon Ben-Noon
		Chief Executive Officer

2